Handelsavisen
prelaunch
Companies ›Healthcare ›222670.KN
22
222670.KN — — Pharmaceuticals

222670.Kn

—
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-6 167,6 %
ROE
35,2 %
Net margin
-7 460,1 %
Debt / equity
-0,36
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the Pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

Business. The company operates in the Pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
35,2 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 222670.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 222670.KN. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the Pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is highly leveraged, with total liabilities of KRW 692.1 billion and total equity of -KRW 406.7 billion, resulting in a negative debt-to-equity ratio of -0.36. Liquidity is constrained, as evidenced by a current ratio of 0.12 and negative free cash flow of KRW -135.7 billion. The company's cash and equivalents of KRW 377.2 billion are insufficient to cover its long-term debt of KRW 146.1 billion, indicating a liquidity risk.

    Profitability is severely challenged, with a net loss of KRW -143.2 billion and an operating loss of KRW -118.4 billion. Return on equity is positive at 35.22%, but this is misleading due to the negative equity base. Gross profit of KRW 10.7 billion is insufficient to cover operating expenses, highlighting operational inefficiencies. These metrics fall well below the industry median for profitability and returns.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits growth opportunities. The absence of segment or geographic breakdown in the financial data suggests a high concentration risk.

    Growth trajectory is negative, with a significant decline in operating and net income. The company's capital expenditure of KRW -252,000 is minimal, indicating limited investment in future growth. The outlook for the current fiscal year is bearish, with no clear path to profitability or revenue expansion.

    Risk factors include a high liquidity risk due to negative free cash flow and insufficient cash reserves to cover debt obligations. The company's dilution risk is low, as shares outstanding remain unchanged between basic and diluted measures. However, the negative equity position and high leverage increase the risk of further dilution if the company requires additional capital.

    Recent events include a significant operating and net loss, which may signal underlying operational or market challenges. No recent filings or transcripts have been disclosed that provide additional context for the financial performance or strategic direction of the company.

    Key takeaways
    • The company is operating at a significant net and operating loss, indicating severe financial distress.
    • Liquidity is constrained, with insufficient cash reserves to cover long-term debt obligations.
    • Return on equity is positive but misleading due to the negative equity base.
    • The company lacks geographic and segment diversification, increasing concentration risk.
    • Growth prospects are limited, with minimal capital expenditure and no clear path to profitability.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    —
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    -$4.07B
    Net cashⓘ
    -$1.08B
    Current ratioⓘ
    0.1
    Debt / equityⓘ
    -0.4
    ROAⓘ
    -50.2%
    ROEⓘ
    35.2%
    Cash conversionⓘ
    92.0%
    CapEx / revenueⓘ
    -1.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-6 167,6 %Bottom quartile
    Net Margin-7 460,1 %Bottom quartile
    ROE35,2 %Best in class
    Capex / Rev-1,3 %Above P75
    D/E-0,36Best in class
    Cash Conv0,92Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 222670.KN Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    222670.KNCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage